Fengqian Chen Unpacks a Promising New Strategy in Solid Tumor Immunotherapy
Fengqian Chen and Aparna Parikh

Fengqian Chen Unpacks a Promising New Strategy in Solid Tumor Immunotherapy

Fengqian Chen, Regional Director of BD and Licensing, U.S. East at Biocytogen, shared on LinkedIn:

“Invikafusp alfa – TCR Vβ-selective bispecific

What if a T-cell engager did not need to recognize the tumor at all?

A new Nature Medicine Phase 1/2 study reports clinical results for invikafusp alfa, a first-in-class bispecific dual T-cell agonist that selectively activates TCR Vβ6/Vβ10 T-cell subsets.

START-001 | NCT05592626

This is fundamentally different from a conventional: TAA × CD3 T-cell engager. Instead of physically bridging a T cell to a tumor-surface antigen, invikafusp aims to: select a T-cell repertoire – expand it – generate endogenous antitumor immunity.

At the optimal biological doses, ORR was 14.8% (4/27), including responses in immunologically difficult tumors such as MSS colorectal cancer and PD-L1-negative NSCLC. Pharmacodynamically, Vβ6/Vβ10 T cells expanded selectively in blood and tumor and maintained a predominantly memory-like phenotype.

The clinical signal is still early – but the product concept is important.

For multispecific antibody discovery, this opens an entirely different target space: not tumor antigen targeting, but immune-repertoire programming. That could be particularly valuable in tumors where no sufficiently selective surface antigen exists for a classical TCE.

It also creates new binder-discovery requirements: Vβ selectivity × agonistic geometry × subset expansion × differentiation state × cytokine release × long-term fitness

The broader lesson: The future of multispecific antibodies may not only be about connecting two cells. It may be about programming which immune cells participate in the response.

Reference: Sullivan RJ, Tschernia NP, Friedman CF, et al. Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial. Nat Med. 2026. DOI: 10.1038/s41591-026-04711-0. (Nature⁠)”

Aparna Parikh, Chief Scientist, Co-Founder, CEO at Reversing Early Recurrence, added:

“This has been a fascinating and exciting program to be part of. We are now taking this forward in a P2 setting in combination with chemo in MSS mCRC in the second line setting at the MGBCI.

I am still excited about the prospect of other TCEs but harnessing a unique T cell population here has certainly been worth following through on.”

Title: Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial

Authors: Ryan J. Sullivan, Nicholas P. Tschernia, Claire F. Friedman, Mercedes Herrera, Guru P. Sonpavde, Kai He, Antoine Italiano, Aurélien Marabelle, Matthieu Roulleaux-Duggar, François-Xavier Danlos, Elena Garralda Cabanas, Alberto Hernando-Calvo, Manuel Pedregal, Aparna Parikh, Gopakumar Iyer, Ahmed Zakari, E. John Wherry, Jeffrey Schlom, Renee N. Donahue, Shannon McCue, Sharon Cross, Karunya Srinivasan, Lisa Benincosa, Madan Katragadda, Zhenming Shun, Kevin Chin, Zhen Su, Ke Liu, Lillian L. Siu, James L. Gulley.

Read the full article.

You may also be interested in: